Table 3.
Fellow eye conversion to neovascular AMD in the MARINA/ANCHOR trials, Barbazetto et al. [39]
| By end of year | A | B = 46.4 % + (A × 53.5 %) |
|---|---|---|
| Cumulative, incremental, conversion rate of the 53.6 % unilateral, neovascular AMD cases at baseline (%) | Bilateral involvement (%) | |
| Baseline | 0.0 | 46.4 |
| Year 1 | 21.2 | 57.7 |
| Year 2 | 38.0 | 66.8 |
| Year 3 | 49.8 | 73.1 |
| Year 4 | 59.5 | 78.3 |
| Year 5 | 67.2 | 82.4 |
| Year 6 | 73.4 | 85.7 |
| Year 7 | 78.5 | 88.5 |
| Year 8 | 82.6 | 90.6 |
| Year 9 | 85.9 | 92.4 |
| Year 10 | 88.6 | 93.9 |
| Year 11 | 90.7 | 95.0 |
| Year 12 | 92.5 | 96.0 |
| Final | 92.5 | 96.0 |
Baseline, year 1 and year 2 prevalences are based upon primary data [39], while years 3–12 are based upon the average incidence of conversion to neovascular during years 1 and 2, using a last observation carried forward (LOCF) methodology with Markov modeling
AMD age-related macular degeneration